The Preemptive Analgesic Efficacy of Nefopam

Seoul National University Bundang Hospital94 enrolled

Overview

Nefopam is administered as a preemptive analgesic drug to the patient undergoing breast cancer surgery. It will be evaluated whether postoperative acute and chronic pain can be reduced.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Breast Neoplasm

Interventions

NefopamDRUG

SalineDRUG

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with breast cancer * Lumpectomy with axillary lymph node dissection or Lumpectomy with sentinel lymph node biopsy * American Society of Anesthesiologists physical status I or II Exclusion Criteria: * Refusal * Seizure * Cardiac disease * Monoamine oxidase inhibitor user * Urologic disease * Glucoma * Preoperative analgesic drug medication * Pregnancy * Recurred breast cancer patient

Locations (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Outcomes

Primary Outcomes

The change of pain numerical rating score from postoperative 30 min until postoperative 3 month

Time frame: Postoperative 30 min, postoperative 1 day, postoperative 1 week, postoperative 3 month

Secondary Outcomes

The dose of ketorolac administered to the patient.

Time frame: postoperative 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.